Aquestive Therapeutics Stock Z Score

AQST Stock

USD 4.51 0.23 4.85%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Aquestive Therapeutics Piotroski F Score and Aquestive Therapeutics Valuation analysis.

For more information on how to buy Aquestive Stock please use our How to Invest in Aquestive Therapeutics guide.

Capital Expenditures is likely to gain to about 1.3 M in 2024, whereas Capital Surpluse is likely to drop slightly above 112.1 M in 2024. At this time, Aquestive Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 92.3 M in 2024, whereas Net Loss is likely to drop (8.3 M) in 2024.

Aquestive Therapeutics Company Z Score Analysis

Aquestive Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Aquestive Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Aquestive Therapeutics is extremely important. It helps to project a fair market value of Aquestive Stock properly, considering its historical fundamentals such as Z Score. Since Aquestive Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aquestive Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aquestive Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Debt	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock	Good Will
Total Assets		-0.22	0.29	-0.38	0.88	0.64	0.27	0.57	-0.49	0.99	-0.44	-0.34	-0.82	-0.34	0.04	-0.8	-0.82	0.64	-0.15	0.75	-0.15	0.75	0.35	-0.15
Total Stockholder Equity	-0.22		0.56	0.98	0.0	0.01	0.09	-0.87	0.37	-0.17	0.33	-0.43	0.59	0.63	-0.71	0.0	0.43	-0.77	0.58	0.39	0.58	0.25	-0.9	0.58
Net Tangible Assets	0.29	0.56		0.52	0.31	-0.09	-0.28	-0.34	-0.54	0.38	-0.44	-0.01	-0.25	-0.24	-0.51	-0.56	-0.35	-0.04	0.25	0.78	0.25	0.7	-0.3	0.25
Retained Earnings	-0.38	0.98	0.52		-0.12	-0.16	-0.06	-0.91	0.4	-0.32	0.34	-0.3	0.67	0.61	-0.66	0.11	0.52	-0.82	0.6	0.26	0.6	0.08	-0.91	0.6
Accounts Payable	0.88	0.0	0.31	-0.12		0.54	0.11	0.33	-0.26	0.88	-0.32	-0.29	-0.56	-0.05	0.09	-0.79	-0.69	0.37	-0.07	0.71	-0.07	0.64	0.13	-0.07
Long Term Debt	0.64	0.01	-0.09	-0.16	0.54		0.75	0.23	0.13	0.63	0.03	-0.72	-0.26	0.15	-0.14	-0.17	-0.18	0.21	0.05	0.48	0.05	0.5	-0.08	0.05
Net Receivables	0.27	0.09	-0.28	-0.06	0.11	0.75		0.06	0.33	0.23	0.48	-0.72	0.04	0.38	-0.32	0.12	0.08	-0.08	0.09	0.15	0.09	0.28	-0.12	0.09
Total Liab	0.57	-0.87	-0.34	-0.91	0.33	0.23	0.06		-0.44	0.52	-0.39	0.13	-0.77	-0.63	0.61	-0.25	-0.62	0.92	-0.29	0.01	-0.29	0.07	0.87	-0.29
Short Long Term Debt	-0.49	0.37	-0.54	0.4	-0.26	0.13	0.33	-0.44		-0.54	0.8	-0.41	0.83	0.89	-0.08	0.62	0.8	-0.68	0.41	-0.42	0.41	-0.56	-0.56	0.41
Total Current Assets	0.99	-0.17	0.38	-0.32	0.88	0.63	0.23	0.52	-0.54		-0.48	-0.31	-0.81	-0.36	0.02	-0.81	-0.83	0.62	-0.14	0.8	-0.14	0.8	0.32	-0.14
Short Term Debt	-0.44	0.33	-0.44	0.34	-0.32	0.03	0.48	-0.39	0.8	-0.48		-0.33	0.66	0.82	-0.32	0.55	0.57	-0.7	0.36	-0.36	0.36	-0.49	-0.47	0.36
Intangible Assets	-0.34	-0.43	-0.01	-0.3	-0.29	-0.72	-0.72	0.13	-0.41	-0.31	-0.33		-0.14	-0.46	0.55	0.06	-0.15	0.2	-0.48	-0.44	-0.48	-0.34	0.51	-0.48
Common Stock	-0.82	0.59	-0.25	0.67	-0.56	-0.26	0.04	-0.77	0.83	-0.81	0.66	-0.14		0.78	-0.24	0.68	0.94	-0.88	0.39	-0.48	0.39	-0.55	-0.71	0.39
Property Plant Equipment	-0.34	0.63	-0.24	0.61	-0.05	0.15	0.38	-0.63	0.89	-0.36	0.82	-0.46	0.78		-0.3	0.32	0.63	-0.83	0.37	-0.15	0.37	-0.26	-0.69	0.37
Current Deferred Revenue	0.04	-0.71	-0.51	-0.66	0.09	-0.14	-0.32	0.61	-0.08	0.02	-0.32	0.55	-0.24	-0.3		0.02	-0.14	0.55	-0.43	-0.43	-0.43	-0.32	0.74	-0.43
Net Debt	-0.8	0.0	-0.56	0.11	-0.79	-0.17	0.12	-0.25	0.62	-0.81	0.55	0.06	0.68	0.32	0.02		0.83	-0.42	0.28	-0.7	0.28	-0.76	-0.24	0.28
Long Term Debt Total	-0.82	0.43	-0.35	0.52	-0.69	-0.18	0.08	-0.62	0.8	-0.83	0.57	-0.15	0.94	0.63	-0.14	0.83		-0.71	0.43	-0.53	0.43	-0.6	-0.59	0.43
Capital Surpluse	0.64	-0.77	-0.04	-0.82	0.37	0.21	-0.08	0.92	-0.68	0.62	-0.7	0.2	-0.88	-0.83	0.55	-0.42	-0.71		-0.35	0.21	-0.35	0.31	0.85	-0.35
Deferred Long Term Liab	-0.15	0.58	0.25	0.6	-0.07	0.05	0.09	-0.29	0.41	-0.14	0.36	-0.48	0.39	0.37	-0.43	0.28	0.43	-0.35		0.29	1.0	-0.06	-0.58	1.0
Net Invested Capital	0.75	0.39	0.78	0.26	0.71	0.48	0.15	0.01	-0.42	0.8	-0.36	-0.44	-0.48	-0.15	-0.43	-0.7	-0.53	0.21	0.29		0.29	0.88	-0.19	0.29
Long Term Investments	-0.15	0.58	0.25	0.6	-0.07	0.05	0.09	-0.29	0.41	-0.14	0.36	-0.48	0.39	0.37	-0.43	0.28	0.43	-0.35	1.0	0.29		-0.06	-0.58	1.0
Net Working Capital	0.75	0.25	0.7	0.08	0.64	0.5	0.28	0.07	-0.56	0.8	-0.49	-0.34	-0.55	-0.26	-0.32	-0.76	-0.6	0.31	-0.06	0.88	-0.06		0.02	-0.06
Capital Stock	0.35	-0.9	-0.3	-0.91	0.13	-0.08	-0.12	0.87	-0.56	0.32	-0.47	0.51	-0.71	-0.69	0.74	-0.24	-0.59	0.85	-0.58	-0.19	-0.58	0.02		-0.58
Good Will	-0.15	0.58	0.25	0.6	-0.07	0.05	0.09	-0.29	0.41	-0.14	0.36	-0.48	0.39	0.37	-0.43	0.28	0.43	-0.35	1.0	0.29	1.0	-0.06	-0.58

Click cells to compare fundamentals

To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Competition

Predict Aquestive Therapeutics

In accordance with the company's disclosures, Aquestive Therapeutics has a Z Score of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The z score for all United States stocks is 100.0% higher than that of the company.

Aquestive Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aquestive Therapeutics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aquestive Therapeutics could also be used in its relative valuation, which is a method of valuing Aquestive Therapeutics by comparing valuation metrics of similar companies.

Aquestive Therapeutics is currently under evaluation in z score category among its peers.

Aquestive Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Aquestive Therapeutics from analyzing Aquestive Therapeutics' financial statements. These drivers represent accounts that assess Aquestive Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aquestive Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	147.6M	180.0M	148.1M	44.0M	123.7M	141.9M
Enterprise Value	158.6M	188.7M	176.5M	72.8M	133.2M	155.3M

Aquestive Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aquestive Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aquestive Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Aquestive Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in Aquestive Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aquestive Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aquestive Therapeutics' value.

		Shares
Nuveen Asset Management, Llc	2024-06-30	785 K
Qube Research & Technologies	2024-06-30	718.1 K
Essex Investment Management Company, Llc	2024-09-30	707.1 K
Woodline Partners Lp	2024-06-30	601 K
Northern Trust Corp	2024-09-30	581.6 K
Dafna Capital Management Llc	2024-06-30	530 K
Bracebridge Capital, Llc	2024-06-30	428.6 K
Stifel Financial Corp	2024-06-30	397.5 K
Latash Investments, Llc	2024-09-30	243.1 K
Bratton Capital Management, L.p.	2024-06-30	9.8 M
Vr Adviser, Llc	2024-06-30	5.6 M

Aquestive Fundamentals

	Return On Asset	-0.16
	Profit Margin	(0.60) %
	Operating Margin	(0.61) %
	Current Valuation	390.7 M
	Shares Outstanding	91.18 M
	Shares Owned By Insiders	5.00 %
	Shares Owned By Institutions	52.41 %
	Number Of Shares Shorted	10.14 M
	Price To Earning	(1.90) X
	Price To Sales	6.98 X
	Revenue	50.58 M
	Gross Profit	28.29 M
	EBITDA	1.18 M
	Net Income	(7.87 M)
	Cash And Equivalents	17.7 M
	Cash Per Share	0.33 X
	Total Debt	33.32 M
	Debt To Equity	468.20 %
	Current Ratio	1.47 X
	Book Value Per Share	(0.50) X
	Cash Flow From Operations	(6.38 M)
	Short Ratio	7.97 X
	Earnings Per Share	(0.45) X
	Target Price	10.06
	Number Of Employees	135
	Beta	2.82
	Market Capitalization	411.21 M
	Total Asset	57.42 M
	Retained Earnings	(319.08 M)
	Working Capital	22.66 M
	Current Asset	38.38 M
	Current Liabilities	17.95 M
	Net Asset	57.42 M

About Aquestive Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Aquestive Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aquestive Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aquestive Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aquestive Stock Analysis

When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aquestive Therapeutics Stock Z Score

Aquestive Therapeutics Company Z Score Analysis

Z Score

Sum Of

5 Factors

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Aquestive Z Score Driver Correlations

Aquestive Z Score Peer Comparison

Aquestive Therapeutics Current Valuation Drivers

Aquestive Therapeutics ESG Sustainability

Aquestive Therapeutics Institutional Holders

Aquestive Fundamentals

About Aquestive Therapeutics Fundamental Analysis

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Aquestive Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY